EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Identifying Poor Responders to STN DBS in Parkinson Disease: The Role of Rapid Disease Progression in the First Year in Optimal Responders to Levodopa

Francesca Morgante iD, Carlo Alberto Artusi iD, Lucia Ricciardi iD, Marianna Sarchioto, Elisa Montanaro, Mark J Edwards, Leonardo Lopiano, Maurizio Zibetti iD

European Journal of Neurology · 2025-09 · 32 (9)

DOI: 10.1111/ene.70342 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 08.09.2025. Verfasst von Francesca Morgante und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience and Cell Biology Institute, Neuromodulation and Motor Control Section, City St George's University of London, London, UK. Hauptthemen laut MEDLINE: Parkinson Disease, Deep Brain Stimulation, Levodopa, Subthalamic Nucleus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The factors contributing to a poor response to subthalamic nucleus deep brain stimulation (STN‐DBS) in Parkinson's disease (PD) are not yet fully understood. Accordingly, predicting the outcome might be challenging particularly in those who display an optimal response to the Levodopa challenge test.

Objective

To determine which factors may contribute to poor outcome of STN‐DBS in PD.

Methods

We performed a retrospective analysis of consecutive PD patients treated with STN‐DBS. Motor and non‐motor variables were retrieved before surgery and at 1‐year follow‐up. Patients were divided into poor and good DBS responders by a cut‐off value of less than 20% improvement of UPDRS‐II in the OFF‐medication ON‐stimulation condition at 1 year.

Results

Thirty‐two (26.2%) of 122 patients were categorised as poor responders. Before surgery, poor responders had significantly less impairment in activity of daily living and less severe motor severity. Response to levodopa challenge test was similar between poor and good responders. Significant worsening of axial symptoms at 1‐year follow‐up in the off‐medication off‐stimulation condition was found in poor responders. On multivariable linear regression analysis, only the relative change of activity of daily living by dopaminergic medications before surgery predicted its improvement by neurostimulation at 1‐year follow‐up.

Conclusions

Candidates for surgery with less impairment in activities of daily living may have less favourable outcomes after STN‐DBS, despite an optimal response during the pre‐operative Levodopa challenge. The worsening of axial symptoms due to disease progression might contribute to poorer outcomes, underscoring the need for better identification of these symptoms before surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseDeep Brain StimulationLevodopaSubthalamic NucleusAntiparkinson AgentsHumansMaleFemaleMiddle AgedRetrospective StudiesDisease ProgressionAgedTreatment OutcomeFollow-Up StudiesSeverity of Illness Index

Stichwörter der Autor:innen

Parkinson's diseaseSTNactivity of daily livingdeep brain stimulationoutcome

Substanzen

LevodopaAntiparkinson Agents

Autor:innen und Institutionen

  • Neuroscience and Cell Biology Institute, Neuromodulation and Motor Control Section, City St George's University of London, London, UK.
  • Department of Neuroscience 'Rita Levi Montalcini', University of Torino, Torino, Italy.
  • UCSF Weill Institute for Neurosciences, Movement Disorders and Neuromodulation Centre, University of California San Francisco, San Francisco, California, USA.
  • Neurology Department, King's College Hospital NHS Foundation Trust, London, UK.
  • Clinical Psychology Unit, AOU Città Della Salute e Della Scienza, Turin, Italy.
  • Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, UK.

ORCID-Profile: Francesca Morgante, Carlo Alberto Artusi, Lucia Ricciardi, Maurizio Zibetti

Zitieren

APA

Morgante, F., Artusi, C. A., Ricciardi, L., Sarchioto, M., Montanaro, E., Edwards, M. J., Lopiano, L., & Zibetti, M. (2025). Identifying Poor Responders to STN DBS in Parkinson Disease: The Role of Rapid Disease Progression in the First Year in Optimal Responders to Levodopa. European Journal of Neurology, 32(9). https://doi.org/10.1111/ene.70342

Vancouver

Morgante F, Artusi CA, Ricciardi L, Sarchioto M, Montanaro E, Edwards MJ, et al. Identifying Poor Responders to STN DBS in Parkinson Disease: The Role of Rapid Disease Progression in the First Year in Optimal Responders to Levodopa. European Journal of Neurology. 2025;32(9). doi:10.1111/ene.70342

BibTeX
@article{Morgante2025,
  author = {Morgante, Francesca and Artusi, Carlo Alberto and Ricciardi, Lucia and Sarchioto, Marianna and Montanaro, Elisa and Edwards, Mark J and Lopiano, Leonardo and Zibetti, Maurizio},
  title = {Identifying Poor Responders to STN DBS in Parkinson Disease: The Role of Rapid Disease Progression in the First Year in Optimal Responders to Levodopa},
  journal = {European Journal of Neurology},
  year = {2025},
  volume = {32},
  number = {9},
  doi = {10.1111/ene.70342}
}
Kostenlos starten →